Plus Therapeutics Expands Strategic Partnership with Telix IsoTherapeutics for Rhenium-186 Radioisotope Supply
BREAKING NEWS: Plus Therapeutics is pleased to announce the expansion of our strategic agreement with Telix IsoTherapeutics Group, a move that strengthens our supply chain and enhances our ability to deliver critical Rhenium-186 (Re-186) radioisotopes. This expanded collaboration focuses on increasing the availability of key radionuclides and boosting manufacturing capabilities for cancer treatments and advanced therapeutics.
Key Highlights of the Expanded Agreement:
- Production Focus: The agreement will center on the production of the key radionuclide intermediate aluminum perrhenate and the final processing of cGMP-compliant Rhenium-186 (Re-186), a critical component for targeted radiotherapy.
- Scalable Manufacturing: This partnership enables just-in-time manufacturing, supporting scalable production to meet growing demand and ensuring a reliable supply chain for cancer therapies.
- Support for Clinical and Commercial Development: The expanded supply chain will play a crucial role in clinical trials and commercial manufacturing, accelerating the development of novel cancer treatments.
This enhanced strategic collaboration is poised to significantly impact the development and production of innovative radiopharmaceuticals, particularly for the treatment of cancer and other serious diseases requiring targeted radionuclide therapy.
For more information, you can read the full press release: Press Release – Plus Therapeutics Expands Agreement with Telix IsoTherapeutics.
#Rhenium186 #Radioisotopes #RadionuclideTherapy #CancerTherapy #PharmaceuticalPartnership #Radiopharmaceuticals #PlusTherapeutics #TelixIsoTherapeutics #MedicalInnovation #CancerTreatment #ClinicalTrials #ScalableManufacturing #PharmaceuticalResearch #OncologyResearch #RadionuclideProduction #TargetedTherapies
Recent Comments